^
Association details:
| Biomarker: | BRAF G464E |
|---|---|
| Cancer: | Melanoma |
| Drug: | PHI-501 (pan-RAF inhibitor, DDR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1627 / 17 - PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma
Published date:
03/15/2023
Excerpt:
The effect of PHI-501 on anchorage independent growth and cell proliferation compared to vemurafenib or belvarafenib (pan-RAF inhibitor) were tested in A375 (BRAF V600E), C8161 (BRAF G464E) and SK-MEL-2 (NRAS Q61R) melanoma cell lines...PHI-501 showed 3- to 119-fold more effective growth inhibition than other RAF inhibitors, vemurafenib and belvarafenib, in SK-MEL-2 (GI50: 0.15 µM for PHI-501 vs 7.13 µM and 0.37 µM, respectively) and C8161 (GI50: 0.33 µM for PHI-501 vs 39.56 µM and 2.10 µM, respectively) melanoma cell lines...
